Authors: Rodrigues, D.C.; Da Cunha, C.N.O.; Faria, A.M.; Panassolo, V.P.; Martins, L.H.R.; De Souza, M.V.N.; De Souza, M.C.F.D.; Munhoz, L.S.; Da Costa De Avila, L.F.; Ramos, D.F.; Scaini, C.J.
Source: Journal of Helminthology, v. 99, p. e19, 2025
Publisher: Cambridge University Press
Abstract
This study aimed to identify a camphor derivative with activity against Toxocara canis larvae and evaluate its cytotoxicity, in silico bioavailability, and in vivo activity in Swiss mice infected with this parasite. Three compounds were tested in vitro in duplicate at a concentration of 1.0 to 0.05 mg/mL in a microplate containing 100 T. canis larvae in RPMI-1640 medium incubated for 48 h at 37°C and 5% CO2. The compound (E)-2-((1,7,7-trimethylbicyclo [2.2.1] heptan-2-ylidene)amino)phenol (C2) presented a minimum larvicidal concentration (MLC) of 0.25 mg/mL and was selected for the subsequent steps. This compound showed 100% cell viability in MLC and adequate bioavailability in computational models. Two subsequent in vivo tests were performed on Swiss mice inoculated with 500 T. canis infective eggs through intragastric (IG) intubation, one at 10 days post-inoculation (n=5) and the other at 30 days post-inoculation (n=10). The selected compound (10 mg/kg, via IG) and two controls (albendazole, 40 mg/kg, IG and phosphate buffered saline 0,15M, pH 7,2, via IG) were used for this evaluation.
Document Type: Research Article
DOI: 10.1017/S0022149X25000094
Publication date: 10 de fevereiro de 2025
